(CercleFinance.com) – Cellectis will present preclinical data on “smart” CAR T cells edited by TALEN allowing better targeting of solid tumors, at the annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held in Boston from 8 to November 12, 2022.
Cellectis, which uses its pioneering TALEN genome-editing technology to develop innovative therapies for the treatment of serious diseases, today announced that preclinical data on TALEN-edited “smart” CAR T cells that can overcome key challenges targeting solid tumors.
On site, Cellectis will present several posters, including one on these “smart” CAR T cells and another on innovative T cell engineering strategies.